Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01124019|
Recruitment Status : Completed
First Posted : May 14, 2010
Last Update Posted : October 13, 2014
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||1600 participants|
|Official Title:||SNP Panels and Risk Assessment in Women Undergoing Mammography|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||October 2012|
|Actual Study Completion Date :||October 2012|
A random sample of 600 women undergoing screening mammography
BIRADS score of 4
An additional 600 women determined to have a Breast Imaging Reporting and Data System (BIRADS) score of 4 as determined by final mammogram results.
- Predicted Risk Category and Prevention RecommendationsThe predicted risk category and prevention recommendations which are based upon the category each patient falls into after risk assessment using either a traditional or a SNP-based approach. Change in PPV of mannographic biopsy by stratification into low and high risk groups.
- Tests and EvaluationsSecondary Outcome will be determining the number of women who are ordered and/or complete tests and/or evaluations if there are abnormal imaging results during mammography or if they have high lifetime risk. These will be measured through access to the electronic medical records (EMR) and/or through a follow up survey.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01124019
|United States, Pennsylvania|
|Abramson Cancer Center of the University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|
|Principal Investigator:||Susan Domchek, MD||Abramson Cancer Center of the University of Pennsylvania|